BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:givastomig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of givastomig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04900818-10902@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:givastomig: Phase 1 readout est. (NCT04900818)
DESCRIPTION:givastomig\, phase 1\, Gastric Cancer.\nStudy: Study of TJ03372
 1 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors\nEstim
 ated primary completion: December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/givastomig#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04900818
URL:https://assetmemo.bio/drug/givastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432295-10902@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:givastomig: Phase 2 readout est. (NCT07432295)
DESCRIPTION:givastomig\, phase 2\, Gastric Cancer.\nStudy: Givastomig Combi
 ned With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metas
 tatic Gastric Cancer (GIVA-2)\nEstimated primary completion: March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/givastomig#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07432295
URL:https://assetmemo.bio/drug/givastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
